{"id":6236,"date":"2019-12-08T12:39:05","date_gmt":"2019-12-08T11:39:05","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/dr-jean-paul-kress-ist-neuer-ceo-der-morphosys-ag\/"},"modified":"2020-06-11T11:19:35","modified_gmt":"2020-06-11T09:19:35","slug":"dr-jean-paul-kress-ist-neuer-ceo-der-morphosys-ag","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/dr-jean-paul-kress-ist-neuer-ceo-der-morphosys-ag\/","title":{"rendered":"Dr. Jean-Paul Kress is new CEO of MorphoSys AG"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Dr. Jean-Paul Kress is new CEO of MorphoSys AG<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]The biotech company is currently establishing its first commercial presence in the US[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]In June the Supervisory Board of MorphoSys AG appointed Dr. Jean-Paul Kress as its new Chief Executive Officer (CEO) with effect from September 1, 2019. Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong track record of commercial and operational leadership in various senior management roles in North America and Europe. His focus has been on operations, corporate development and especially the commercialization of innovative products. Prior to joining MorphoSys, Dr. Kress worked at Syntimmune, Sanofi Genzyme, Gilead and Eli Lilly. In his new position, Dr. Kress succeeds Dr. Simon Moroney, who stepped down as CEO on \u00adSeptember 1, 2019.
\n[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_single_image image=”6234″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]Dr. Jean-Paul Kress<\/strong>, CEO, MorphoSys[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 MorphoSys<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]\u201cI am delighted to welcome Jean-Paul Kress as the new CEO of MorphoSys,\u201d said Dr. Marc Cluzel, Chairman of the Supervisory Board of MorphoSys. \u201cMorphoSys is at a turning point in its business evolution, bringing its first product to the market and establishing a commercial presence in the US. Jean-Paul’s industry expertise will perfectly complement the experienced MorphoSys Management Board.\u201d<\/p>\n

\u201cOn behalf of the entire Supervisory Board, I want to express our sincere gratitude to Simon Moroney for fulfilling the role as CEO over the past 27 years. His tireless efforts for MorphoSys have contributed substantially to making it the biopharmaceutical success story that it is today.\u201d Marc Cluzel continued.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n \n
\n MorphoSys AG <\/div>\n\n